Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Glioblastoma 9Central Nervous System Neoplasms 6Brain Neoplasms 6Oligodendroglioma 3Gliosarcoma 3Astrocytoma 3Sarcoma 2Optic Nerve Glioma 2Neoplasm Metastasis 2Glioma 2Ependymoma 2Zollinger-Ellison Syndrome 1Wilms Tumor 1Vipoma 1Unspecified Adult Solid Tumor, Protocol Specific 1Somatostatinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Retinoblastoma 1Recurrence 1Prolactinoma 1Pituitary Neoplasms 1Pheochromocytoma 1Ovarian Neoplasms 1Osteosarcoma 1Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Neuroectodermal Tumors 1Neuroblastoma 1Multiple Endocrine Neoplasia Type 2b 1

Interventions

avelumab 2Capecitabine 2veliparib 1domatinostat 1antineoplaston AS 2-1 1antineoplaston A10 1Temozolomide 1Radiosurgery 1Omacor 1Leucovorin 1Ipilimumab 1Fluorouracil 1Cyclophosphamide 1Complementary Therapies 1Cisplatin 1Biological Therapy 1Bevacizumab 1ALT-803 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Carcinoma, Merkel Cell × Temozolomide × Clear all
NCT02831179 2017-09-28

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Vanderbilt-Ingram Cancer Center

Phase 1 Withdrawn
DermatologicEndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adrenal Cortex Neoplasms, Carcinoid Tumor, Vipoma, Glucagonoma, Insulinoma, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

Data powered by HemOnc (CC BY 4.0) Colophon âš¡